Arcellx Inc ACLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACLX is a good fit for your portfolio.
News
-
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
-
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-
Arcellx Shares Rise Premarket on Expanded Gilead Collaboration
-
Gilead Invests Further in Arcellx, Extends Collaboration
-
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
-
Arcellx Shares Drop After Patient Death Draws Clinical Hold from FDA
Trading Information
- Previous Close Price
- $53.55
- Day Range
- $52.59–54.89
- 52-Week Range
- $30.74–75.10
- Bid/Ask
- $54.50 / $54.53
- Market Cap
- $2.90 Bil
- Volume/Avg
- 692,182 / 456,144
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.06
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 130
- Website
- https://www.arcellx.com
Comparables
Valuation
|
Metric
|
ACLX
|
EQRX
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.95 | 0.97 | 4.32 |
Price/Sales | 24.06 | — | 23.86 |
Price/Cash Flow | — | — | — |
Price/Earnings
ACLX
EQRX
PTGX
Financial Strength
|
Metric
|
ACLX
|
EQRX
|
PTGX
|
|---|---|---|---|
Quick Ratio | 5.94 | 18.43 | 16.54 |
Current Ratio | 6.06 | 18.78 | 16.71 |
Interest Coverage | −23.39 | — | — |
Quick Ratio
ACLX
EQRX
PTGX
Profitability
|
Metric
|
ACLX
|
EQRX
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | −6.26% | −15.72% | −16.60% |
Return on Equity (Normalized) | −12.08% | −16.71% | −18.20% |
Return on Invested Capital (Normalized) | −13.11% | −21.31% | −23.45% |
Return on Assets
ACLX
EQRX
PTGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kmdfmgpmd | Rcpl | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dznlcthn | Ljkbcf | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rbhgtyv | Rmdryz | $98.1 Bil | |
MRNA
| Moderna Inc | Ckwmdwt | Qfzk | $39.7 Bil | |
ARGX
| argenx SE ADR | Shyswyf | Yhqq | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Hbhfgjfzg | Vpwc | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fgfgdxkzd | Qrjvr | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cfqzhbdn | Hdhrmf | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yhbkgrdr | Dmplcs | $12.5 Bil | |
INCY
| Incyte Corp | Sbvyxgkqz | Dwxlnq | $11.8 Bil |